~~<i id='6F5066CB1C'><strike id='6F5066CB1C'><tt id='6F5066CB1C'><pre id='6F5066CB1C'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：Wikipedia 2025-10-01 10:33:31 - browse：18

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Researchers use wearables data and AI to predict preterm birth risk

knowledge

explore

leisure time

hotspot

focus

entertainment

TheALSdrugtofersenismarketedasQalsodyintheU.S.BiogenLONDON—Neurologistsandpatientadvocatesareupinarm

WSS

Mindstrong's demise and the future of mental health care

Listen: Who gets the credit for GLP

Mindstrong's demise and the future of mental health care

People with mental disorders often marry others with same

WHO recommends dropping component of many flu vaccines

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

focus

hotspot

knowledge

Walensky prepares to leave CDC — and Congress — behind

People with mental disorders often marry others with same

After affirmative action ruling, medical educators look to 'holistic review'

Intercept Pharmaceuticals sells itself for less than $1 billion

The high cost of giving birth even with insurance

Ionis has late

What does generative AI mean for health care? We asked experts

Shingles, which affected Dianne Feinstein, is on the rise

Bright Health sells Medicare Advantage business to Molina

FDA advisers vote against ALS treatment from BrainStorm

explore

After a drawn out lobbying fight, ARPA

Menendez indictment could see pharma lose a key ally

Young boy dies in trial for Pfizer Duchenne gene therapy

Multiple sclerosis has subtypes with different best treatments: study

Address the ethical violations that led to 'Three Identical Strangers'

Medicare Advantage 2025 payments will dip, Biden administration says

leisure time

hotspot

focus

entertainment